Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27019758 | 0.82 | NR1H2 (0.35) | NR1H2NR1H3PTPN1PDE4BTSHR | |
| SCHEMBL4301733 | 0.81 | NR1H2 (0.36) | NR1H2NR1H3PTPN1PDE4BPREP | |
| SCHEMBL19972969 | 0.78 | PTPN1 (0.37) | NR1H2NR1H3PTPN1PDE4BPREP | |
| SCHEMBL29770685 | 0.76 | TSHR (0.40) | NR1H2NR1H3PTPN1PDE4BTSHR | |
| SCHEMBL35211177 | 0.76 | TSHR (0.40) | NR1H2NR1H3PTPN1PDE4BTSHR | |
| SCHEMBL24513562 | 0.74 | NR1H2 (0.40) | NR1H2NR1H3PTPN1PDE4BPREP | |
| SCHEMBL2932735 | 0.74 | NR1H2 (0.40) | NR1H2NR1H3PTPN1PDE4BPREP | |
| SCHEMBL31109910 | 0.74 | NR1H2 (0.40) | NR1H2NR1H3PTPN1PDE4BPREP | |
| SCHEMBL30220406 | 0.74 | NR1H2 (0.40) | NR1H2NR1H3PTPN1PDE4BPREP | |
| SCHEMBL30886791 | 0.74 | NR1H2 (0.40) | NR1H2NR1H3PTPN1PDE4BPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | NR1H2 449/4885NR1H3 380/4885PTPN1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.